Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, Ichihara T, Kuroda Y, Maeda S, Kasuga M
Second Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan.
Eur J Cancer. 2001 Jan;37(2):204-9. doi: 10.1016/s0959-8049(00)00371-3.
Glucose uptake is mediated by glucose transporter (Glut) proteins, which exhibit altered expression in a variety of malignant neoplasms. Glut1 expression is thought to be a potential marker for malignant transformation. The aim of the present study was to investigate the expression of Glut1 protein in colorectal adenomas, T1 and T2 stage carcinomas. Immunohistochemical detection of Glut1 protein was examined in 141 formalin-fixed and paraffin-embedded colorectal tumour specimens (57 adenomas, 84 carcinomas). The degree of Glut1 immunostaining of a specimen was graded according to the proportion of Glut1-positive cells in it; absent (positive cells are 0%), weakly positive (less than 10%), moderately positive (10-50%), and strongly positive (more than 50%). Glut1 expression was present in 18% of the adenomas with low-grade dysplasia, and in 63% of the adenomas with high-grade dysplasia. The positivity in such lesions was usually weak, but was moderate in 8% of the adenomas with high grade dysplasia. For the carcinomas, there were significant correlations between Glut1-positivity and depth of invasion (T1 45% versus T2 74%, P<0.01), histological differentiation (well 49% versus moderately to poorly 74%, P< 0.05) and morphological type (polypoid 42% versus depressed 73%, P< 0.05), if the cut-off value was set at 10% of cells. In conclusion, we clarified the relationship between Glut1 expression and clinicopathological features in T1 and T2 stage colorectal carcinomas, and our results suggested a high malignant potential of the depressed-type carcinoma.
葡萄糖摄取由葡萄糖转运蛋白（Glut）介导，这些蛋白在多种恶性肿瘤中表达改变。Glut1表达被认为是恶性转化的一个潜在标志物。本研究的目的是调查Glut1蛋白在大肠腺瘤、T1和T2期癌中的表达。对141例福尔马林固定石蜡包埋的大肠肿瘤标本（57例腺瘤，84例癌）进行了Glut1蛋白的免疫组化检测。根据标本中Glut1阳性细胞的比例对Glut1免疫染色程度进行分级：无（阳性细胞为0%）、弱阳性（少于10%）、中度阳性（10%-50%）和强阳性（超过50%）。低级别不典型增生的腺瘤中18%有Glut1表达，高级别不典型增生的腺瘤中63%有Glut1表达。此类病变中的阳性通常较弱，但在8%的高级别不典型增生腺瘤中为中度阳性。对于癌，如果将临界值设定为细胞的10%，则Glut1阳性与浸润深度（T1为45%，T2为74%，P<0.01）、组织学分化（高分化为49%，中分化至低分化为74%，P<0.05）和形态学类型（息肉样为42%，凹陷型为73%，P<0.05）之间存在显著相关性。总之，我们阐明了T1和T2期大肠癌中Glut1表达与临床病理特征之间的关系，我们的结果提示凹陷型癌具有较高的恶性潜能。
